|
KMID : 0941820060160020155
|
|
Korean Journal of Clinical Pharmacy
2006 Volume.16 No. 2 p.155 ~ p.164
|
|
|
Clinical Pharmacogenomics of Drug Metabolizing Enzymes and its Clinical Applicaition
|
|
Kim Kyung-Im
Kim Seung-Hee
Park Ji-Eun
Chae Han-Jung
Choi Ji-Sun
Shin Wan-Gyoon
Son In-Ja
Oh Jung-Mi
|
|
|
Abstract
|
|
|
|
Great inter-variability in drug response and advese drug reactions is related to inter-variability of drug bioavailability, drug interaction and patient’s disease and physyological state that cause change in absorption, distribution, metabolism and excretion of drugs. However, these alone do not sufficiently predict and explain inter-variability in drug response. In recent studies, It is reported that inter-variability in drug response and adverse drug reactions nay largely resultred from genetically determined differences in drug absorption, distribution, metabolism and drug target proteins. Especially, the major human drug-metabolizing enzymes such as CYP450, N-acetyl transferase, thiopurine S-methyl transferase, glutathione S-transferase are identified as the major gene variants that cause inter-individual variability in drug’s reponse and adverse drug reactions. These variations may have most significant implications for those drugs that gave narrow therapeutic index and serious adverse drug reactions. Therefore, the genetic variation such as polymorphyisms in drug metabolizing enzymes can affect the response of individuals to drugs that are used in the treatment of depressionm psychosis, cancer, cardiovascular disorders, ulcer and gastrointesinal disorders, pain and epilepsy, among others. This review describes the pharmacogenomics of the drug metabolizing enzymes associated with the drug response and its clinical applications.
|
|
|
KEYWORD
|
|
|
Clinical pharmacogenomics, Inter-individual variability, Drug metabolizing enzyme, CytochromeP450, Phase II enzyme
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|